Masarova L, Mascarenhas J, Rampal R, Hu W, Livingston R, Pemmaraju N
Cancer. 2024; 131(1):e35661.
PMID: 39616447
PMC: 11694550.
DOI: 10.1002/cncr.35661.
Spivak J
J Clin Med. 2024; 13(22).
PMID: 39598101
PMC: 11595126.
DOI: 10.3390/jcm13226957.
Sugimoto Y, Nagaharu K, Ohya E, Ohishi K, Tawara I, Ito T
Int J Hematol. 2024; 120(6):684-693.
PMID: 39467899
DOI: 10.1007/s12185-024-03862-5.
Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian J, Pemmaraju N
Br J Haematol. 2024; 205(1):48-60.
PMID: 38853641
PMC: 11245372.
DOI: 10.1111/bjh.19557.
Chen C, Chen J, Lin A, Yu L, Hou H
Ann Hematol. 2024; 103(6):1947-1965.
PMID: 38652240
PMC: 11090937.
DOI: 10.1007/s00277-024-05754-4.
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
Morsia E, Torre E, Martini F, More S, Poloni A, Olivieri A
Int J Mol Sci. 2024; 25(3).
PMID: 38338802
PMC: 10855502.
DOI: 10.3390/ijms25031524.
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.
England J, Szuber N, Sirhan S, Dunne T, Cerquozzi S, Hill M
Leukemia. 2024; 38(3):570-578.
PMID: 38321107
DOI: 10.1038/s41375-024-02155-4.
The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.
Pettersson H, Adamsson J, Johansson P, Nilsson S, Palmqvist L, Andreasson B
Front Oncol. 2023; 13:1190305.
PMID: 37637067
PMC: 10451068.
DOI: 10.3389/fonc.2023.1190305.
Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms.
Braunstein E, Imada E, Pasca S, Wang S, Chen H, Alba C
Leukemia. 2022; 37(3):627-635.
PMID: 36543879
DOI: 10.1038/s41375-022-01797-6.
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Sobas M, Kiladjian J, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih L
Blood Adv. 2022; 6(17):5171-5183.
PMID: 35802458
PMC: 9631631.
DOI: 10.1182/bloodadvances.2022007201.
Clinical features associated with thrombotic events in children with myeloproliferative neoplasms.
Shimano K, Vanderpoel V, Stone H, Resar L, Kucine N
Am J Hematol. 2022; 97(9):E353-E355.
PMID: 35751861
PMC: 9378702.
DOI: 10.1002/ajh.26646.
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T
Int J Hematol. 2022; 116(2):215-227.
PMID: 35430707
DOI: 10.1007/s12185-022-03341-9.
Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J, Chatain N, Sofias A, Lammers T, Koschmieder S
Cells. 2021; 10(12).
PMID: 34944059
PMC: 8700229.
DOI: 10.3390/cells10123551.
The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms.
Aswad M, Kissova J, Ovesna P, Rihova L, Penka M
In Vivo. 2021; 35(6):3345-3353.
PMID: 34697168
PMC: 8627720.
DOI: 10.21873/invivo.12632.
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.
Ross D, Babon J, Tvorogov D, Thomas D
Haematologica. 2021; 106(5):1244-1253.
PMID: 33472356
PMC: 8094080.
DOI: 10.3324/haematol.2020.262691.
Applied genomics in MPN presentation.
Moliterno A, Kaizer H
Hematology Am Soc Hematol Educ Program. 2020; 2020(1):434-439.
PMID: 33275725
PMC: 7727573.
DOI: 10.1182/hematology.2020000128.
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.
Moliterno A, Ginzburg Y, Hoffman R
Blood. 2020; 137(9):1145-1153.
PMID: 33237986
PMC: 8215376.
DOI: 10.1182/blood.2020008043.
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses.
Debureaux P, Cassinat B, Soret-Dulphy J, Mora B, Verger E, Maslah N
Blood Adv. 2020; 4(15):3708-3715.
PMID: 32777065
PMC: 7422133.
DOI: 10.1182/bloodadvances.2020002414.
Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.
Kucine N
Curr Hematol Malig Rep. 2020; 15(2):141-148.
PMID: 32172359
PMC: 7234912.
DOI: 10.1007/s11899-020-00571-8.
From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Stein B, Martin K
Hematology Am Soc Hematol Educ Program. 2019; 2019(1):397-406.
PMID: 31808903
PMC: 6913438.
DOI: 10.1182/hematology.2019001318.